Pre-clinical evaluation of cysteamine bitartrate as a therapeutic agent for mitochondrial respiratory chain disease

Cysteamine bitartrate is a US Food and Drug Administration-approved therapy for nephropathic cystinosis also postulated to enhance glutathione biosynthesis. We hypothesized this antioxidant effect may reduce oxidative stress in primary mitochondrial respiratory chain (RC) disease, improving cellular...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Hum Mol Genet
Autori principali: Guha, Sujay, Konkwo, Chigoziri, Lavorato, Manuela, Mathew, Neal D, Peng, Min, Ostrovsky, Julian, Kwon, Young-Joon, Polyak, Erzsebet, Lightfoot, Richard, Seiler, Christoph, Xiao, Rui, Bennett, Michael, Zhang, Zhe, Nakamaru-Ogiso, Eiko, Falk, Marni J
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
General Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6522065/
https://ncbi.nlm.nih.gov/pubmed/30668749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/hmg/ddz023
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi